Saturday, Dec 10, 2022
×
Outlook.com
×

Lupin

Lupin Gets USFDA Nod For Generic HIV Drug 

The Mumbai-based company said it is the exclusive first filer for 800 mg tablets and is eligible for 180-day exclusivity

04 October 2022

Lupin's Somerset Manufacturing Plant Receives EIR From US FDA

The US Food and Drug Administration (US FDA) had inspected the facility in March 2022, the company said in a regulatory filing


Lupin Gets USFDA Nod To Market Generic Drug

The company has received tentative approval from the United States Food and Drug Administration for its abbreviated new drug application for Tenofovir Alafenamide tablets


Lupin Gets USFDA Nod For Generic Drug To Treat Seizures

The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of rufinamide tablets of strengths 100 mg, 200 mg, and 400 mg

18 August 2022

Lupin Gets USFDA Nod For Generic Drug

The company has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Ivacaftor tablets, 150 mg strength.


Lupin Receives USFDA Approval For Anti-Depressant Drug

The approval granted by the US Food and Drug Administration is for the abbreviated new drug application Desvenlafaxine extended-release tablets of strength 25 mg, the company said in a regulatory filing.

14 April 2022

Lupin Gets USFDA Nod For Generic Blood Pressure Lowering Drug

The Mumbai-based company said it has received the nod from the US Food and Drug Administration (FDA) to market Azilsartan Medoxomil tablets

25 July 2022

Advertisement

Lupin Launches Generic Contraceptive Drug In US

The Mumbai-based drug maker has launched the product in the US market under exclusive license, marketing and distribution agreement with Slayback Pharma LLC

07 April 2022

Advertisement
07 April 2022
Lupin Launches Generic Contraceptive Drug In The US

Lupin Launches Generic Contraceptive Drug In The US

The Mumbai-based drugmaker has launched the product in the US market under an exclusive license, marketing, and distribution agreement with Slayback Pharma LLC


07 April 2022
Lupin Acquires Portfolio Of Brands From Anglo-French Drugs & Industries

Lupin Acquires Portfolio Of Brands From Anglo-French Drugs & Industries

The acquisition will strengthen the company's India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements, and...


24 March 2022
Lupin Gets USFDA Nod For Generic Product

Lupin Gets USFDA Nod For Generic Product

The Mumbai-based company's product is the generic version of Viatris Specialty LLC's Revatio


08 February 2022
Lupin Gets USFDA Nod For Generic Version Of Arformoterol Tartrate Inhalation Solution

Lupin Gets USFDA Nod For Generic Version Of Arformoterol Tartrate Inhalation Solution

The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of arformoterol tartrate inhalation solution 15...


01 February 2022
Lupin, Axantia Team Up For Licensing And Distribution For Pegfilgrastim

Lupin, Axantia Team Up For Licensing And Distribution For Pegfilgrastim

The Mumbai-based drug firm has entered into a license, supply and technology sharing agreement with Axantia Holding, a leading pharmaceutical company in the...


Advertisement

19 January 2022
Lupin Shenzhen Foncoo Team Up To Introduce Products In China

Lupin Shenzhen Foncoo Team Up To Introduce Products In China

This is the company's first partnership arrangement in China and reinforces drug maker's commitment to bringing high-quality generic and complex generic...


16 January 2022
Sun Pharma, Lupin Recall Products In US market

Sun Pharma, Lupin Recall Products In US market

Sun Pharma is recalling 696 bottles of Pregabalin capsules (50 mg), used for the treatment of epilepsy, anxiety, and nerve pain, in the US market. 


07 January 2022
Lupin Launches Covid-19 Drug Molnulup In India

Lupin Launches Covid-19 Drug Molnulup In India

It has been given emergency use authorisation by the (DCGI) for the treatment of adult Covid-19 patients who have a high risk of progression of the disease.


28 October 2021
Buzzing Stocks: PNB Shares Tumble Nearly 10 Per Cent, Lupin Plunges falls Over 2 Per Cent

Buzzing Stocks: PNB Shares Tumble Nearly 10 Per Cent, Lupin Plunges falls Over 2 Per Cent

The state-owned bank reported a 78 per cent rise in net profit to Rs 1,105 crore for the second quarter ended on September 30 despite a fall in income.


Advertisement
Advertisement
Advertisement
Advertisement
Advertisement